帝人株式会社の減損損失および特別損益に関するお知らせ

This document reports on the impairment losses and special profits recorded by Teijin Corporation for the fourth quarter of the fiscal year ending March 2025. It details the 28 billion yen impairment loss related to the sales rights of diabetes treatments acquired by its subsidiary, Teijin Pharma, due to increased competition and pricing revisions. Additionally, it discusses the decision to transfer shares owned by Teijin Holdings USA, leading to a 65.8 billion yen valuation loss and an 85.4 billion yen provision for bad debts. These losses are accounted for in the fiscal forecasts for March 2025, with no impact on consolidated earnings.